{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:58:40Z","timestamp":1786985920178,"version":"build-2736575974"},"reference-count":195,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007526","name":"University of Tours","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007526","id-type":"DOI","asserted-by":"crossref"}]},{"name":"R\u00e9gion Centre Val de Loire"},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009895","name":"Canc\u00e9rop\u00f4le Grand Ouest","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009895","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CHRU de Tours, Tours' Hospital oncology association ACORT"},{"name":"CANCEN"},{"DOI":"10.13039\/501100004792","name":"Minist\u00e8re de l\u2019enseignement sup\u00e9rieur et de la recherche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Calcium"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ceca.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T11:04:14Z","timestamp":1559732654000},"page":"38-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Lipid metabolism and Calcium signaling in epithelial ovarian cancer"],"prefix":"10.1016","volume":"81","author":[{"given":"Sana","family":"Kouba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobna","family":"Ouldamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Chantome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Vandier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Goupille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Potier-Cartereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.ceca.2019.06.002_bib0005","first-page":"v23","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Colombo","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0010","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1023\/A:1008217129273","article-title":"Malignant effusions contain lysophosphatidic acid (LPA)-like activity","volume":"9","author":"Westermann","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0015","first-page":"1223","article-title":"Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients","volume":"1","author":"Xu","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbalip.2012.08.015","article-title":"Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy","volume":"1831","author":"Brindley","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ceca.2019.06.002_bib0025","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc1143","article-title":"The emerging role of lysophosphatidic acid in cancer","volume":"3","author":"Mills","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0030","first-page":"313","article-title":"Lysophosphatidic acid receptors in cancer pathobiology","volume":"29","author":"Tsujiuchi","year":"2014","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0035","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","article-title":"PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment","volume":"71","author":"Obermajer","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0262-1746(86)90084-3","article-title":"Fatty acid composition and arachidonic acid metabolites in ascitic fluid of patients with ovarian cancer","volume":"22","author":"Punnonen","year":"1986","journal-title":"Prostaglandins Leukot. Med."},{"key":"10.1016\/j.ceca.2019.06.002_bib0045","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1158\/0008-5472.CAN-12-4572","article-title":"Pivotal role of the lipid Raft SK3-Orai1 complex in human cancer cell migration and bone metastases","volume":"73","author":"Chantome","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0050","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1016\/j.bbamem.2015.06.009","article-title":"Plasma membrane calcium channels in cancer: alterations and consequences for cell proliferation and migration","volume":"1848","author":"Deliot","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ceca.2019.06.002_bib0055","first-page":"15","article-title":"Potassium channels and proliferation and migration of breast cancer cells","volume":"61","author":"Zhang","year":"2009","journal-title":"Sheng Li Xue Bao"},{"key":"10.1016\/j.ceca.2019.06.002_bib0060","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s40610-017-0072-8","article-title":"Store-operated Ca(2+) entry as a prostate Cancer biomarker - a riddle with perspectives","volume":"3","author":"Kappel","year":"2017","journal-title":"Curr. Mol. Biol. Rep."},{"key":"10.1016\/j.ceca.2019.06.002_bib0065","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/sj.cdd.4402162","article-title":"Ion channels in death and differentiation of prostate cancer cells","volume":"14","author":"Prevarskaya","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ceca.2019.06.002_bib0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1574892811308010018","article-title":"Calcium channels and prostate cancer","volume":"8","author":"Shapovalov","year":"2013","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.ceca.2019.06.002_bib0075","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1038\/s41598-017-14230-1","article-title":"Ca(2+) protein alpha 1D of CaV1.3 regulates intracellular calcium concentration and migration of colon cancer cells through a non-canonical activity","volume":"7","author":"Fourbon","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ceca.2019.06.002_bib0080","doi-asserted-by":"crossref","first-page":"36168","DOI":"10.18632\/oncotarget.8786","article-title":"SK3\/TRPC1\/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline","volume":"7","author":"Gueguinou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ceca.2019.06.002_bib0085","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbamcr.2017.01.005","article-title":"Calcium remodeling in colorectal cancer","volume":"1864","author":"Villalobos","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0090","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/aje\/kwh103","article-title":"Aggregation of ovarian cancer with breast, ovarian, colorectal, and prostate cancer in first-degree relatives","volume":"159","author":"Tung","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0095","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2016.06.003","article-title":"Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy","volume":"165","author":"Jaffres","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ceca.2019.06.002_bib0100","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.bbamem.2017.04.003","article-title":"Towards understanding the molecular basis of ion channel modulation by lipids: mechanistic models and current paradigms","volume":"1859","author":"Poveda","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ceca.2019.06.002_bib0105","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.bbamem.2015.03.022","article-title":"TRP channels interaction with lipids and its implications in disease","volume":"1848","author":"Taberner","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ceca.2019.06.002_bib0110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-biophys-101211-113227","article-title":"Bacterial mechanosensitive channels--MscS: evolution\u2019s solution to creating sensitivity in function","volume":"41","author":"Naismith","year":"2012","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.ceca.2019.06.002_bib0115","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1152\/jn.00226.2018","article-title":"Role of lysophosphatidic acid in ion channel function and disease","volume":"120","author":"Hernandez-Araiza","year":"2018","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0120","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/jid.2012.370","article-title":"Lysophosphatidic acid promotes cell migration through STIM1- and Orai1-mediated Ca2+(i) mobilization and NFAT2 activation","volume":"133","author":"Jans","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0125","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00424-013-1422-x","article-title":"Arachidonic acid activation of BKCa (Slo1) channels associated to the beta1-subunit in human vascular smooth muscle cells","volume":"466","author":"Martin","year":"2014","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ceca.2019.06.002_bib0130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ceca.2009.02.001","article-title":"Arachidonic acid, ARC channels, and Orai proteins","volume":"45","author":"Shuttleworth","year":"2009","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ceca.2019.06.002_bib0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-319-57732-6_8","article-title":"STIM-TRP pathways and microdomain organization: Ca(2+) influx channels: the Orai-STIM1-TRPC complexes","volume":"993","author":"Bodnar","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00249-017-1216-8","article-title":"Constitutive calcium entry and cancer: updated views and insights","volume":"46","author":"Mignen","year":"2017","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.ceca.2019.06.002_bib0145","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.bbamcr.2014.02.019","article-title":"KCa and Ca(2+) channels: the complex thought","volume":"1843","author":"Gueguinou","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ceca.2019.06.002_bib0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0155","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ceca.2019.06.002_bib0160","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ceca.2019.06.002_bib0165","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.3747\/co.24.3824","article-title":"Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline","volume":"24","author":"Francis","year":"2017","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0170","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-#","article-title":"International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption","volume":"58","author":"Rose","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0175","first-page":"273","article-title":"A pooled analysis of 12 cohort studies of dietary fat, cholesterol and egg intake and ovarian cancer","volume":"17","author":"Genkinger","year":"2006","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ceca.2019.06.002_bib0180","doi-asserted-by":"crossref","first-page":"43099","DOI":"10.18632\/oncotarget.5525","article-title":"Dietary fat and fatty acid intake and epithelial ovarian cancer risk: evidence from epidemiological studies","volume":"6","author":"Hou","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ceca.2019.06.002_bib0185","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1207\/S15327914NC402_2","article-title":"Dietary fat intake and risk of epithelial ovarian cancer: a meta-analysis of 6,689 subjects from 8 observational studies","volume":"40","author":"Huncharek","year":"2001","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0190","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.canep.2014.07.011","article-title":"Dietary fat intake and risk of epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition","volume":"38","author":"Merritt","year":"2014","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0195","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3945\/ajcn.115.118588","article-title":"Nutrient-wide association study of 57 foods\/nutrients and epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition study and the Netherlands Cohort Study","volume":"103","author":"Merritt","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ceca.2019.06.002_bib0200","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/djm159","article-title":"Low-fat dietary pattern and cancer incidence in the women\u2019s health initiative dietary modification randomized controlled trial","volume":"99","author":"Prentice","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ceca.2019.06.002_bib0205","doi-asserted-by":"crossref","first-page":"37390","DOI":"10.18632\/oncotarget.8940","article-title":"Dietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studies","volume":"7","author":"Qiu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ceca.2019.06.002_bib0210","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1055-9965.1521.13.9","article-title":"A case-control study of diet and the risk of ovarian cancer","volume":"13","author":"Pan","year":"2004","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ceca.2019.06.002_bib0215","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/ije\/dyr130","article-title":"Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project","volume":"40","author":"Bjorge","year":"2011","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0220","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jnci\/88.1.32","article-title":"Prospective study of serum micronutrients and ovarian cancer","volume":"88","author":"Helzlsouer","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ceca.2019.06.002_bib0225","doi-asserted-by":"crossref","first-page":"9635","DOI":"10.1007\/s13277-016-4799-2","article-title":"Is cholesterol a mediator of cold-induced cancer?","volume":"37","author":"Mandal","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0230","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1055-9965.EPI-12-0188","article-title":"Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study","volume":"21","author":"Melvin","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ceca.2019.06.002_bib0235","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/ijc.31758","article-title":"Statin therapy and association with ovarian cancer risk in the New England Case Control (NEC) study","volume":"144","author":"Akinwunmi","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12986-017-0176-4","article-title":"Case-control study of metabolic syndrome and ovarian cancer in Chinese population","volume":"14","author":"Chen","year":"2017","journal-title":"Nutr. Metab. (Lond.)"},{"key":"10.1016\/j.ceca.2019.06.002_bib0245","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.critrevonc.2016.01.002","article-title":"Alcoholic beverages, obesity, physical activity and other nutritional factors, and cancer risk: A review of the evidence","volume":"99","author":"Latino-Martel","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0250","first-page":"761","article-title":"Diet and reproductive hormones: a study of vegetarian and nonvegetarian postmenopausal women","volume":"67","author":"Armstrong","year":"1981","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ceca.2019.06.002_bib0255","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJM198212163072502","article-title":"Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women","volume":"307","author":"Goldin","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ceca.2019.06.002_bib0260","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ijc.29471","article-title":"Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: results from the EPIC cohort","volume":"137","author":"Fortner","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CEJ.0000000000000217","article-title":"Ovarian cancer: epidemiology and risk factors","volume":"26","author":"La Vecchia","year":"2017","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.ceca.2019.06.002_bib0270","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbalip.2016.01.012","article-title":"Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCepsilon\/delta-induced ERK pathways","volume":"1861","author":"Chauvin","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ceca.2019.06.002_bib0275","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1063-5823(06)59007-6","article-title":"Regulation of the mechano-gated K2P channel TREK-1 by membrane phospholipids","volume":"59","author":"Chemin","year":"2007","journal-title":"Curr. Top. Membr."},{"key":"10.1016\/j.ceca.2019.06.002_bib0280","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1021\/acsomega.7b00936","article-title":"Singular interaction between an antimetastatic agent and the lipid bilayer: the ohmline case","volume":"2","author":"Herrera","year":"2017","journal-title":"ACS Omega"},{"key":"10.1016\/j.ceca.2019.06.002_bib0285","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0955-0674(00)00231-3","article-title":"Lipid and mechano-gated 2P domain K(+) channels","volume":"13","author":"Patel","year":"2001","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0290","first-page":"9","article-title":"Modulation of Ras\/ERK and phosphoinositide signaling by long-chain n-3 PUFA in breast cancer and their potential complementary role in combination with targeted drugs","author":"Serini","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.ceca.2019.06.002_bib0295","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.clinbiochem.2007.06.007","article-title":"Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer","volume":"40","author":"Delimaris","year":"2007","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ceca.2019.06.002_bib0300","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-16-1647","article-title":"Integrative systemic and local metabolomics with impact on survival in high-grade serous ovarian Cancer","volume":"23","author":"Bachmayr-Heyda","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0305","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ijgo.12645","article-title":"The positive predictive value of low-density lipoprotein for recurrence-free survival in ovarian cancer","volume":"143","author":"Zhu","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ceca.2019.06.002_bib0310","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ygyno.2009.09.027","article-title":"Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers","volume":"116","author":"Li","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0315","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7555\/JBR.32.20170096","article-title":"Association of serum lipids and severity of epithelial ovarian cancer: an observational cohort study of 349 Chinese patients","volume":"32","author":"Zhang","year":"2018","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0320","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9125238","article-title":"Statin as a combined therapy for advanced-stage ovarian Cancer: a propensity score matched analysis","author":"Chen","year":"2016","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.ceca.2019.06.002_bib0325","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pharmthera.2017.02.021","article-title":"Fatty acid synthase - Modern tumor cell biology insights into a classical oncology target","volume":"177","author":"Buckley","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ceca.2019.06.002_bib0330","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1158\/0008-5472.CAN-16-3044","article-title":"Metabolic markers and statistical prediction of serous ovarian Cancer aggressiveness by ambient ionization mass spectrometry imaging","volume":"77","author":"Sans","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0335","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5702026","article-title":"High membranous expression of fatty acid transport protein 4 is associated with tumorigenesis and tumor progression in clear cell renal cell carcinoma","author":"Kim","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ceca.2019.06.002_bib0340","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41388-017-0093-z","article-title":"Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis","volume":"37","author":"Ladanyi","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ceca.2019.06.002_bib0345","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12032-014-0391-z","article-title":"Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer","volume":"32","author":"Cai","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0350","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0046-8177(97)90177-5","article-title":"Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival","volume":"28","author":"Gansler","year":"1997","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0355","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/285191","article-title":"Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas","author":"Ueda","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0360","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/ijc.29261","article-title":"Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells","volume":"136","author":"Veigel","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0365","doi-asserted-by":"crossref","first-page":"11600","DOI":"10.18632\/oncotarget.14591","article-title":"Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells","volume":"8","author":"Wagner","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ceca.2019.06.002_bib0370","doi-asserted-by":"crossref","first-page":"10715","DOI":"10.1073\/pnas.0403390101","article-title":"Inhibition of fatty acid synthase (FAS) suppresses HER2\/neu (erbB-2) oncogene overexpression in cancer cells","volume":"101","author":"Menendez","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ceca.2019.06.002_bib0375","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/bjc.2012.246","article-title":"Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas","volume":"107","author":"Rahman","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0380","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/1878-0261.12396","article-title":"Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment","volume":"13","author":"Reinartz","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0385","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/abio.2001.5000","article-title":"Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids","volume":"290","author":"Xiao","year":"2001","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ceca.2019.06.002_bib0390","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13059-016-0956-6","article-title":"A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome","volume":"17","author":"Reinartz","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0395","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s13277-010-0123-8","article-title":"Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer","volume":"32","author":"Sedlakova","year":"2011","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0400","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jama.280.8.719","article-title":"Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers","volume":"280","author":"Xu","year":"1998","journal-title":"Jama"},{"key":"10.1016\/j.ceca.2019.06.002_bib0405","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.7150\/jca.20639","article-title":"Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model","volume":"9","author":"Xue","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0410","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12944-015-0071-9","article-title":"Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis","volume":"14","author":"Li","year":"2015","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ceca.2019.06.002_bib0415","doi-asserted-by":"crossref","first-page":"e5583","DOI":"10.1371\/journal.pone.0005583","article-title":"Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis","volume":"4","author":"Murph","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ceca.2019.06.002_bib0420","first-page":"10","article-title":"Molecular mechanisms regulating organ-specific metastases in epithelial ovarian carcinoma","author":"Barbolina","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ceca.2019.06.002_bib0425","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","article-title":"Mechanisms of transcoelomic metastasis in ovarian cancer","volume":"7","author":"Tan","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0430","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.trecan.2017.09.004","article-title":"Lysophosphatidate signaling: the tumor microenvironment\u2019s new Nemesis","volume":"3","author":"Benesch","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0435","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2017.00024","article-title":"The unique molecular and cellular microenvironment of ovarian Cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0440","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/0008-5472.CAN-05-1292","article-title":"Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells","volume":"66","author":"Ren","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0445","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1194\/jlr.M014985","article-title":"Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid","volume":"52","author":"Dusaulcy","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0450","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00216-017-0813-9","article-title":"Quantitative proteomic analysis of murine white adipose tissue for peritoneal cancer metastasis","volume":"410","author":"Feist","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ceca.2019.06.002_bib0455","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ceca.2019.06.002_bib0460","first-page":"2482","article-title":"Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2","volume":"6","author":"Eder","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0465","doi-asserted-by":"crossref","first-page":"C163","DOI":"10.1152\/ajpcell.00001.2009","article-title":"Epidermal growth factor increases lysophosphatidic acid production in human ovarian cancer cells: roles for phospholipase D2 and receptor transactivation","volume":"298","author":"Snider","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0470","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/stem.2279","article-title":"Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism","volume":"34","author":"Seo","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.ceca.2019.06.002_bib0475","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0014-5793(97)00411-0","article-title":"Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis","volume":"410","author":"Gaits","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ceca.2019.06.002_bib0480","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood-2014-03-562538","article-title":"Paraneoplastic thrombocytosis: the secrets of tumor self-promotion","volume":"124","author":"Lin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ceca.2019.06.002_bib0485","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00404-016-4212-9","article-title":"Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies","volume":"295","author":"Menczer","year":"2017","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ceca.2019.06.002_bib0490","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2016.12.002","article-title":"Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression","volume":"150","author":"Swier","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0495","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/13697137.2017.1406911","article-title":"Clinicopathological and prognostic significance of platelet count in patients with ovarian cancer","volume":"21","author":"Zhou","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.ceca.2019.06.002_bib0500","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s11745-012-3691-0","article-title":"Serum autotaxin is not a useful biomarker for ovarian cancer","volume":"47","author":"Nakamura","year":"2012","journal-title":"Lipids"},{"key":"10.1016\/j.ceca.2019.06.002_bib0505","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00428-018-2418-x","article-title":"Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma","volume":"473","author":"Onallah","year":"2018","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ceca.2019.06.002_bib0510","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1096\/fj.12-207597","article-title":"Elevated and secreted phospholipase A(2) activities as new potential therapeutic targets in human epithelial ovarian cancer","volume":"26","author":"Cai","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.ceca.2019.06.002_bib0515","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3109\/10799893.2015.1026444","article-title":"Lysophosphatidic acid signaling in ovarian cancer","volume":"35","author":"Jesionowska","year":"2015","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0520","first-page":"10","article-title":"Lysophospholipid signaling in the epithelial ovarian Cancer tumor microenvironment","author":"Xu","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ceca.2019.06.002_bib0525","first-page":"17880","article-title":"Expressions of lysophosphatidic acid receptors in the development of human ovarian carcinoma","volume":"8","author":"Si","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.ceca.2019.06.002_bib0530","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ygyno.2006.10.016","article-title":"The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms","volume":"104","author":"Wang","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0535","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.3892\/or.2015.4216","article-title":"The significance of the altered expression of lysophosphatidic acid receptors, autotaxin and phospholipase A2 as the potential biomarkers in type 1 endometrial cancer biology","volume":"34","author":"Wasniewski","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ceca.2019.06.002_bib0540","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1186\/s12885-016-2865-1","article-title":"LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study","volume":"16","author":"Yu","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0545","first-page":"5370","article-title":"Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer","volume":"59","author":"Goetzl","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120071","article-title":"Decreased peritoneal ovarian cancer growth in mice lacking expression of lipid phosphate phosphohydrolase 1","volume":"10","author":"Nakayama","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ceca.2019.06.002_bib0555","first-page":"3534","article-title":"Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer","volume":"9","author":"Tanyi","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0560","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/cncr.22184","article-title":"Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival","volume":"107","author":"Diefenbach","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0565","doi-asserted-by":"crossref","first-page":"9415","DOI":"10.1158\/0008-5472.CAN-05-0516","article-title":"Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies","volume":"65","author":"Springett","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0570","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.bjc.6602528","article-title":"Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis","volume":"92","author":"Niesporek","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0575","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1124\/pr.114.009217","article-title":"Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer","volume":"66","author":"Bruntz","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ceca.2019.06.002_bib0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2014.109","article-title":"Promising pharmacological directions in the world of lysophosphatidic Acid signaling","volume":"23","author":"Stoddard","year":"2015","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.ceca.2019.06.002_bib0585","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0590","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2018\/e530s","article-title":"Eicosanoids and cancer","volume":"73","author":"Gomes","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.ceca.2019.06.002_bib0595","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1055-9965.EPI-18-0392","article-title":"Prediagnostic serum levels of fatty acid metabolites and risk of ovarian Cancer in the prostate, lung, colorectal, and ovarian (PLCO) Cancer screening trial","volume":"28","author":"Hada","year":"2018","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ceca.2019.06.002_bib0600","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1158\/1078-0432.CCR-0132-03","article-title":"Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2\/neu, and poor outcome in serous ovarian carcinoma","volume":"10","author":"Erkinheimo","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0605","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ygyno.2013.02.011","article-title":"Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies","volume":"129","author":"Lee","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0610","doi-asserted-by":"crossref","first-page":"88152","DOI":"10.18632\/oncotarget.21538","article-title":"COX-2 expression in ovarian cancer: an updated meta-analysis","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ceca.2019.06.002_bib0615","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1073\/pnas.1803999116","article-title":"Suppression of chemotherapy-induced cytokine\/lipid mediator surge and ovarian cancer by a dual COX-2\/sEH inhibitor","volume":"116","author":"Gartung","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ceca.2019.06.002_bib0620","doi-asserted-by":"crossref","first-page":"39582","DOI":"10.18632\/oncotarget.8659","article-title":"The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer","volume":"7","author":"Suri","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ceca.2019.06.002_bib0625","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1471-2407-11-214","article-title":"Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients","volume":"11","author":"Legge","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0630","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.clinthera.2014.06.015","article-title":"Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials","volume":"36","author":"Chen","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ceca.2019.06.002_bib0635","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1093\/annonc\/mds107","volume":"23","author":"Reyners","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0640","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ygyno.2012.08.010","article-title":"17beta Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma","volume":"127","author":"Szajnik","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0645","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1933719108316390","article-title":"Lipoxygenase pathway receptor expression in ovarian cancer","volume":"15","author":"Rocconi","year":"2008","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.ceca.2019.06.002_bib0650","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1006\/bbrc.2001.5301","article-title":"Human granulosa-lutein cells express functional EP1 and EP2 prostaglandin receptors","volume":"285","author":"Harris","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ceca.2019.06.002_bib0655","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1677\/joe.0.1350153","article-title":"Carbachol increases intracellular free calcium concentrations in human granulosa-lutein cells","volume":"135","author":"Mayerhofer","year":"1992","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0660","first-page":"1209","article-title":"Effect of oxytocin on free intracellular Ca2+ levels and progesterone release by human granulosa-lutein cells","volume":"77","author":"Mayerhofer","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ceca.2019.06.002_bib0665","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1210\/jc.2003-032219","article-title":"Two types of calcium channels in human ovarian endocrine cells: involvement in steroidogenesis","volume":"89","author":"Agoston","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ceca.2019.06.002_bib0670","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1210\/endo.137.9.8756543","article-title":"P2-purinoreceptor evoked changes in intracellular calcium oscillations in single isolated human granulosa-lutein cells","volume":"137","author":"Lee","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.ceca.2019.06.002_bib0675","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1477-7827-7-28","article-title":"Identification and characterization of Ca2+-activated K+ channels in granulosa cells of the human ovary","volume":"7","author":"Traut","year":"2009","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0680","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ceca.2018.07.011","article-title":"ORAI channels and cancer","volume":"74","author":"Chalmers","year":"2018","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ceca.2019.06.002_bib0685","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.bbamem.2014.12.016","article-title":"Ion channel expression as promising cancer biomarker","volume":"1848","author":"Lastraioli","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ceca.2019.06.002_bib0690","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1152\/physrev.00044.2016","article-title":"Ion Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies?","volume":"98","author":"Prevarskaya","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ceca.2019.06.002_bib0695","doi-asserted-by":"crossref","first-page":"C457","DOI":"10.1152\/ajpcell.00064.2015","article-title":"STIM and Orai proteins as novel targets for cancer therapy. a review in the theme: cell and molecular processes in cancer metastasis","volume":"309","author":"Vashisht","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0700","first-page":"455","article-title":"Brain natriuretic peptide (BNP)-like immunoreactivity in the central nervous system of the crested newt","volume":"36","author":"Franzoni","year":"1992","journal-title":"Eur. J. Histochem."},{"key":"10.1016\/j.ceca.2019.06.002_bib0705","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.bbamem.2014.08.016","article-title":"Altered calcium signaling in cancer cells","volume":"1848","author":"Stewart","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ceca.2019.06.002_bib0710","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4419-6066-5_10","article-title":"Integrins and ion channels in cell migration: implications for neuronal development, wound healing and metastatic spread","volume":"674","author":"Becchetti","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0715","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrn2093","article-title":"Neuronal calcium sensor proteins: generating diversity in neuronal Ca2+ signalling","volume":"8","author":"Burgoyne","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ceca.2019.06.002_bib0720","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1574892811308010004","article-title":"The need for calcium channels in cell proliferation","volume":"8","author":"Capiod","year":"2013","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.ceca.2019.06.002_bib0725","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nrm1150","article-title":"Regulation of cell death: the calcium-apoptosis link","volume":"4","author":"Orrenius","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0730","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2374","article-title":"Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival","volume":"8","author":"Roderick","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0735","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1242\/jcs.114.12.2223","article-title":"Mechanisms of capacitative calcium entry","volume":"114","author":"Putney","year":"2001","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.ceca.2019.06.002_bib0740","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1127883","article-title":"CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry","volume":"312","author":"Vig","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ceca.2019.06.002_bib0745","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrc.2017.18","article-title":"The calcium-cancer signalling nexus","volume":"17","author":"Monteith","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0750","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrc3105","article-title":"Calcium in tumour metastasis: new roles for known actors","volume":"11","author":"Prevarskaya","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0755","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.18632\/oncotarget.2035","article-title":"Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells","volume":"5","author":"Schmidt","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ceca.2019.06.002_bib0760","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1159\/000322327","article-title":"Non-selective cation channel-mediated Ca2+-entry and activation of Ca2+\/calmodulin-dependent kinase II contribute to G2\/M cell cycle arrest and survival of irradiated leukemia cells","volume":"26","author":"Heise","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ceca.2019.06.002_bib0765","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.3748\/wjg.14.4984","article-title":"Calcium signaling and T-type calcium channels in cancer cell cycling","volume":"14","author":"Taylor","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2019.03.025","article-title":"Upregulation of Orai1 and STIM1 expression as well as store-operated Ca(2+) entry in ovary carcinoma cells by placental growth factor","author":"Abdelazeem","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ceca.2019.06.002_bib0775","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0780","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.celrep.2015.06.033","article-title":"STIM1 mediates hypoxia-driven hepatocarcinogenesis via interaction with HIF-1","volume":"12","author":"Li","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ceca.2019.06.002_bib0785","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/35077544","article-title":"The TRP ion channel family","volume":"2","author":"Clapham","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ceca.2019.06.002_bib0790","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature02196","article-title":"TRP channels as cellular sensors","volume":"426","author":"Clapham","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ceca.2019.06.002_bib0795","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1111\/bph.12721","article-title":"TRP channels and STIM\/ORAI proteins: sensors and effectors of cancer and stroma cell migration","volume":"171","author":"Nielsen","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0800","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbadis.2007.05.006","article-title":"TRP channels in cancer","volume":"1772","author":"Prevarskaya","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ceca.2019.06.002_bib0805","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/156800913804486629","article-title":"TRPC channels and their splice variants are essential for promoting human ovarian cancer cell proliferation and tumorigenesis","volume":"13","author":"Zeng","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ceca.2019.06.002_bib0810","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3892\/ijo.2015.3254","article-title":"Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer","volume":"48","author":"Liu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0815","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4161\/auto.19627","article-title":"Mammalian PIK3C3\/VPS34: the key to autophagic processing in liver and heart","volume":"8","author":"Jaber","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.ceca.2019.06.002_bib0820","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3892\/ijo.2013.1819","article-title":"Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer","volume":"42","author":"Yin","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0825","doi-asserted-by":"crossref","first-page":"17163","DOI":"10.1074\/jbc.M114.558288","article-title":"Role of autophagy in cisplatin resistance in ovarian cancer cells","volume":"289","author":"Wang","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ceca.2019.06.002_bib0830","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/onc.2008.475","article-title":"Transient receptor potential channel C3 contributes to the progression of human ovarian cancer","volume":"28","author":"Yang","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ceca.2019.06.002_bib0835","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1038\/sj.onc.1210545","article-title":"TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)\/NFAT-dependent pathways","volume":"26","author":"Lehen\u2019kyi","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ceca.2019.06.002_bib0840","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/07357907.2011.568565","article-title":"Blockade of T-type Ca(2+) channels inhibits human ovarian cancer cell proliferation","volume":"29","author":"Li","year":"2011","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ceca.2019.06.002_bib0845","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1677\/ERC-09-0152","article-title":"Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1\/2 activation regulated by calcium and protein kinase C{delta}","volume":"17","author":"Mertens-Walker","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ceca.2019.06.002_bib0850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041664","article-title":"Role of KCNMA1 in breast cancer","volume":"7","author":"Oeggerli","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ceca.2019.06.002_bib0855","doi-asserted-by":"crossref","first-page":"43924","DOI":"10.18632\/oncotarget.9721","article-title":"KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ceca.2019.06.002_bib0860","first-page":"1377","article-title":"Low expression of KCNN3 may affect drug resistance in ovarian cancer","volume":"18","author":"Liu","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ceca.2019.06.002_bib0865","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1038\/s41598-017-04292-6","article-title":"Kca3.1 activation via P2y2 purinergic receptors promotes human ovarian Cancer cell (Skov-3) migration","volume":"7","author":"Robles-Martinez","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ceca.2019.06.002_bib0870","doi-asserted-by":"crossref","first-page":"viii13","DOI":"10.1093\/annonc\/mdx446","article-title":"Acquired chemotherapy resistance in ovarian cancer","volume":"28","author":"Christie","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0875","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/14737140.2017.1398088","article-title":"Optimizing treatment in recurrent epithelial ovarian cancer","volume":"17","author":"Corrado","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ceca.2019.06.002_bib0880","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijpharm.2017.09.060","article-title":"Co-delivery strategies to overcome multidrug resistance in ovarian cancer","volume":"533","author":"Khan","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ceca.2019.06.002_bib0885","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1080\/14656566.2017.1328055","article-title":"Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies","volume":"18","author":"Tomao","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ceca.2019.06.002_bib0890","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-15-0456","article-title":"T-type Ca2+ channel inhibition sensitizes ovarian Cancer to carboplatin","volume":"15","author":"Dziegielewska","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ceca.2019.06.002_bib0895","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1007\/s13277-015-4081-z","article-title":"Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells","volume":"37","author":"Samuel","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ceca.2019.06.002_bib0900","doi-asserted-by":"crossref","first-page":"33896","DOI":"10.18632\/oncotarget.26084","article-title":"Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BclxL strategies through Mcl-1 down-regulation","volume":"9","author":"Bonnefond","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ceca.2019.06.002_bib0905","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1159\/000438547","article-title":"Impact of Na+\/Ca2+ exchangers on therapy resistance of ovary carcinoma cells","volume":"37","author":"Pelzl","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ceca.2019.06.002_bib0910","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1194\/jlr.R046458","article-title":"LPA receptor signaling: pharmacology, physiology, and pathophysiology","volume":"55","author":"Yung","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0915","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2000.tb06550.x","article-title":"Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer","volume":"905","author":"Fang","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ceca.2019.06.002_bib0920","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1016\/j.febslet.2014.05.052","article-title":"Inhibitory role of polyunsaturated fatty acids on lysophosphatidic acid-induced cancer cell migration and adhesion","volume":"588","author":"Kim","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ceca.2019.06.002_bib0925","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/0470862580.ch8","article-title":"Activation, subunit composition and physiological relevance of DAG-sensitive TRPC proteins","volume":"258","author":"Gudermann","year":"2004","journal-title":"Novartis Found. Symp."},{"issue":"Pt 1","key":"10.1016\/j.ceca.2019.06.002_bib0930","first-page":"159","article-title":"Protein kinase C activates non-capacitative calcium entry in human platelets","volume":"529","author":"Rosado","year":"2000","journal-title":"J. Physiol. (Paris)"},{"key":"10.1016\/j.ceca.2019.06.002_bib0935","series-title":"Store-Independent Orai Channels Regulated by STIM","first-page":"197","author":"Zhang","year":"2018"},{"key":"10.1016\/j.ceca.2019.06.002_bib0940","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3892\/ijmm.2012.1022","article-title":"A mechanism underlying the effects of polyunsaturated fatty acids on breast cancer","volume":"30","author":"Zhang","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ceca.2019.06.002_bib0945","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/onc.2011.231","article-title":"TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling","volume":"31","author":"Fiorio Pla","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ceca.2019.06.002_bib0950","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12935-018-0529-8","article-title":"Arachidonic acid-induced Ca(2+) entry and migration in a neuroendocrine cancer cell line","volume":"18","author":"Goswamee","year":"2018","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ceca.2019.06.002_bib0955","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ccr.2014.04.025","article-title":"Remodeling of channel-forming ORAI proteins determines an oncogenic switch in prostate cancer","volume":"26","author":"Dubois","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ceca.2019.06.002_bib0960","first-page":"1073","article-title":"The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer","volume":"63","author":"Tanyi","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ceca.2019.06.002_bib0965","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1074\/jbc.M308133200","article-title":"Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1","volume":"279","author":"Yamada","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ceca.2019.06.002_bib0970","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/1055-9965.EPI-13-0515","article-title":"Dietary intake and ovarian cancer risk: a systematic review","volume":"23","author":"Crane","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ceca.2019.06.002_bib0975","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000485624","article-title":"The expression of HSD17B12 is associated with COX-2 expression and is increased in high-grade epithelial ovarian Cancer","volume":"94","author":"Kemilainen","year":"2018","journal-title":"Oncology"}],"container-title":["Cell Calcium"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143416019300685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143416019300685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T20:27:54Z","timestamp":1758918474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143416019300685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":195,"alternative-id":["S0143416019300685"],"URL":"https:\/\/doi.org\/10.1016\/j.ceca.2019.06.002","relation":{},"ISSN":["0143-4160"],"issn-type":[{"value":"0143-4160","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid metabolism and Calcium signaling in epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Calcium","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ceca.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}